A preclinical study found that antiangiogenic therapies targeting the vascular endothelial growth factor (VEGF)-dependent signaling pathway promoted alleviation of hypoxia, efficient tumor infiltration by CD8-positive T cells, and reduced recruitment of tumor-associated macrophages.10, 11, 12, 13, 14 Therefore, the addition of an antiangiogenic drug to ICI may enhance antitumor immune responses by normalizing the tumor microenvironment. Here, CD8A is linked to neoplasm.